Sanofi (Euronext:SAN; NYSE:SNY) is no longer purusing 19 of the 27 NMEs that were in Phase II or Phase III/registration at the start of 2009. Some of the programs missed Phase II endpoints, while others were discontinued after the company concluded the value proposition wasn't there from either the patient or payer perspective. Sources: BCIQ: BioCentury Online Intelligence; Sanofi SEC filings and website

Product

Description

Indication

Then - YE08

Now

Partner